All News

bechets.jpg

Organ Involvement with Behçet’s

d Jack Cush, MD

A review of patient data from the International AutoInflammatory Disease Alliance (AIDA) Network registry identifying those with mucocutaneous Behçet’s disease (BD) may progres to major organ involvement (MOI)m especially at later stages.

Read Article
Clot.DVT_.VTE_.blood_.jpg

A New Disease Activity Score for Antiphospholipid Syndrome?

d EurekAlert!

APS is a systemic autoimmune disorder. It is characterised by the presence of antiphospholipid antibodies and a broad spectrum of clinical features, causing obstetric as well as thrombotic, microvascular and non-thrombotic (TMN) symptoms.

Read Article
psA.fil_.Hands_.jpg

APEX Study: Inhibition of structural damage progression with Guselkumab in Psoriatic Arthritis

d Jack Cush, MD

Guselkumab, a human IL-23 inhibitor, was evaluated in patients with active psoriatic arthritis (PsA) and shown to have both clinical and radiographic benefits at weeks 24 and 48.

Read Article
juvDM1.jpg

Pulse Steroids and Mycophenolate in Juvenile Dermatomyositis

d Jack Cush, MD

JAMA Dermatology has published a pilot study demonstrating the safety and efficacy of intermittent intravenous methylprednisolone pulse (IVMP) therapy plus mycophenolate in 28 patients with juvenile dermatomyositis (JDM).

Read Article
106-0674_IMG.JPG

Seeking Musculoskeletal Care

d Jack Cush, MD

A report entitled The Burden of Musculoskeletal Diseases in the United States (BMUS) report was published by the US Bone and Joint Decade (USBJD) with input from rheumatology, orthopedic surgery, physical medicine and rehabilitation regarding musculoskeletal care.

Read Article
USA,States,map

Rheumatology Supply and Demand (2009 - 2024)

d Jack Cush, MD

A retrospective review of US rheumatology manpower and training between 2009 and 2024 shows that US rheumatology training has become competitive with an increasing surplus of applicants compared to available training positions, which have also increased over time.

Read Article
ACR Applauds Bipartisan Support for Prior Authorization Reform Bill The ACR commended the more than 295 bipartisan, bicameral cosponsors of The Improving Seniors’ Timely Access to Care Act, which, if enacted, would reform the prior authorization process for Medicare Advantage https://t.co/n0MKkSqRwO
Dr. John Cush RheumNow ( View Tweet)
RheumNow Live 2026 Rheumatologists don’t just attend #RheumNowLive — they shape it. Join the conversation that defines our field. 🕓 Early Bird registration open through 12/1 👉 https://t.co/zYYC2350tE #RheumTwitter #Rheumatology #CME #RNL2026 #MedTwitter #HCPcommunity https://t.co/ejOB2WmOiv

Links:

Dr. John Cush RheumNow ( View Tweet)
25-Hydroxyvitamin D levels and Lupus Outcomes Lupus patients entering a prospective cohort study with low vitamin D levels faced doubled all-cause mortality risk and tripled risk for major cardiovascular events during follow-up averaging 6 years, researchers said. https://t.co/4nhACulIw0
Dr. John Cush RheumNow ( View Tweet)
Serious infections w/ adalimumab. Marketscan MarketScan claims study (1/17-12/20) of ADA Rx in Hidradenitis Supprativa (n 1650) or psoriasis(8699). Risk of SIE & hospitalization greater w/ HS (HR 1.53); esp for sepsis & GU infxn https://t.co/2qa7O2v6fm

Links:

Dr. John Cush RheumNow ( View Tweet)

Seeking Musculoskeletal Care A report entitled The Burden of Musculoskeletal Diseases in the United States (BMUS) was published by the USBJD with input from rheumatology, orthopedic surgery, physical medicine and rehabilitation regarding musculoskeletal care. https://t.co/KGYHrQYADE
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Head-to-Head Clinical Trials https://t.co/LpvqQRP06b https://t.co/YkXYvUuJWx

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective review of 113 AOSD pts, median age 45yrs, ferritin 4626 (IQR 1169–14,239). Advanced Rx (IVIG, IL-1, IL-6) required in 15 (13.3%), NOT predicted by ferritin levels, either measured continuously or by quartiles. Ferritin is not a reliable biomarker in AOSD. https://t.co/pHEPeIf9u2
Dr. John Cush RheumNow ( View Tweet)
Lupus Nephritis study of 136 pts followed 121 mos. Median time to wean GC to 7.5 mg/day, 5 mg/day & D/C was 9, 12 & 29 months post-Dx. Predictors of shorter time to D/C= Sustained CR/SLEDAI-2K≤4, membranous LN, & HCQ. Prolonged GC & renal flares increase damage accrual

Dr. John Cush RheumNow ( View Tweet)

Review of neonatal Fc receptor (FcRn) blockers, being developed by J&J, argenx & UCB, showing utility in autoimmune dz as they reduce autoantibodies. FcRn inhibitor market may be worth USD 3.3 billion by 2035. Approved for myasthenia gravis & being developed in Sjögren’s, SLE, https://t.co/mBUla87dK5
Dr. John Cush RheumNow ( View Tweet)
Japanese ANSWER cohort (3623 RA pts on bDMARDs or JAKi) included looked at T2T in 118 RA pregnancies. 93% had full-term deliveries; 85% w/ remission or LDA maintained throughout preg. 35/118 cont' bDMARDs during preg & had signif lower DAS28-CRP vs those D/C (n 24) (P = 0.007). https://t.co/uG8m7RzSiU
Dr. John Cush RheumNow ( View Tweet)
Serum IL-1Ra levels are elevated in Lg vessel vasculitis - 21 active, Rx naive LVV pts (13 GCA, 8 TAK), IL-1Ra higher in TAK (465 pg/mL) & GCA (385 pg/mL) vs NLs (170). IL-6 also incr. in LVV, but IL-1β & IFN-γ incr in GCA & ^ IL-17in TAK. IL-1Ra correlate w/ CRP in GCA & https://t.co/TFDpK5DqcJ
Dr. John Cush RheumNow ( View Tweet)
Australian Vaccine study (2019 - 2021) - w/in 12 mos of b/tsDMARD initiation 73% (11,225/15,460) recv influenza vaccination. High-dose Flu vax used in 28% in 60–69 yo, but > 80% older than 70yo. Only 9.7% recv pneumococcal & 2.4% zoster Zostavax or Shingrix) vax w/in 6 months of https://t.co/xoGTWMUi1L
Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 56 articles & 72,677 RA pts w/ a Dz duration of 9.7 yrs looked at biologic persistence. In csDMARD-IR, over 5 yrs TCZ (66%) & golimumab (62%) best. In bDMARD-IR, ABA (45%) & ETN (41%) best. Lower Rx survival predicted by steroids, hi Dz activity, & female https://t.co/tepL0A9Fwb
Dr. John Cush RheumNow ( View Tweet)
PROSPERO meta-analysis shows an effect of diet on #RA risk. 8 independent studies (n=270,121) showed a reduced risk of incident RA with Anti-inflammatory (OR 0.56; 0.31–0.99), Mediterranean (OR 0.88; 0.78–0.99), and HEI (OR 0.60; 0.25–1.47), but not DASH diets https://t.co/Qr9lXWRAED
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×